Published in J Med Chem on July 01, 2004
Role of the intestinal bile acid transporters in bile acid and drug disposition. Handb Exp Pharmacol (2011) 1.14
SIB-DOTA: a trifunctional prosthetic group potentially amenable for multi-modal labeling that enhances tumor uptake of internalizing monoclonal antibodies. Bioorg Med Chem (2012) 0.81
Strategies for the preparation of bifunctional gadolinium(III) chelators. Curr Org Synth (2011) 0.78
Bile acid binding protein: a versatile host of small hydrophobic ligands for applications in the fields of MRI contrast agents and bio-nanomaterials. Comput Struct Biotechnol J (2013) 0.76
Increase of leishmanicidal and tubercular activities using steroids linked to aminoquinoline. Org Med Chem Lett (2012) 0.75
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol (2005) 3.93
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol (2013) 3.24
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol (2009) 2.80
C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J Urol (2005) 1.93
Iopamidol as a responsive MRI-chemical exchange saturation transfer contrast agent for pH mapping of kidneys: In vivo studies in mice at 7 T. Magn Reson Med (2011) 1.57
Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins. Int J Cancer (2007) 1.43
Dose-related effects of repeated ETC-216 (recombinant apolipoprotein A-I Milano/1-palmitoyl-2-oleoyl phosphatidylcholine complexes) administrations on rabbit lipid-rich soft plaques: in vivo assessment by intravascular ultrasound and magnetic resonance imaging. J Am Coll Cardiol (2008) 1.41
177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med (2006) 1.23
Radiofrequency ablation of 40 lung neoplasms: preliminary results. AJR Am J Roentgenol (2004) 1.23
Recombinant apolipoprotein A-I(Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ Res (2002) 1.22
Dasatinib: an anti-tumour agent via Src inhibition. Curr Drug Targets (2011) 1.15
Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J Clin Oncol (2006) 1.14
A general MRI-CEST ratiometric approach for pH imaging: demonstration of in vivo pH mapping with iobitridol. J Am Chem Soc (2014) 1.12
Resveratrol inhibits the epidermal growth factor-induced epithelial mesenchymal transition in MCF-7 cells. Cancer Lett (2011) 1.11
Methods for an improved detection of the MRI-CEST effect. Contrast Media Mol Imaging (2009) 1.09
TORCH study: how much longer should we continue to use erlotinib in unselected patients with non-small-cell lung cancer? J Clin Oncol (2012) 1.07
Target therapies in pancreatic carcinoma. Curr Med Chem (2014) 1.01
Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies. J Clin Oncol (2007) 0.99
Image guided therapy: the advent of theranostic agents. J Control Release (2012) 0.97
Molecular determinants in the transport of a bile acid-derived diagnostic agent in tumoral and nontumoral cell lines of human liver. J Pharmacol Exp Ther (2006) 0.96
In vitro and in vivo magnetic resonance detection of tumor cells by targeting glutamine transporters with Gd-based probes. J Med Chem (2006) 0.94
In vivo biodistribution and lifetime analysis of cy5.5-conjugated rituximab in mice bearing lymphoid tumor xenograft using time-domain near-infrared optical imaging. Mol Imaging (2009) 0.94
Present status and perspectives in the treatment of hormone-refractory prostate cancer. Oncology (2005) 0.92
Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design. J Clin Oncol (2002) 0.92
Role of gemcitabine in metastatic breast cancer patients: a short review. Breast (2007) 0.92
Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma. Cancer (2009) 0.92
A newly generated functional antibody identifies Tn antigen as a novel determinant in the cancer cell-lymphatic endothelium interaction. Glycobiology (2009) 0.91
Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis. Expert Opin Biol Ther (2014) 0.89
A multinuclear NMR relaxometry study of ternary adducts formed between heptadentate Gd(III) chelates and L-lactate. Chemistry (2005) 0.89
Evaluation of neovessels in atherosclerotic plaques of rabbits using an albumin-binding intravascular contrast agent and MRI. J Magn Reson Imaging (2008) 0.88
Kinetics of gadobenate dimeglumine in isolated perfused rat liver: MR imaging evaluation. Radiology (2003) 0.87
Dissociation kinetics of open-chain and macrocyclic gadolinium(III)-aminopolycarboxylate complexes related to magnetic resonance imaging: catalytic effect of endogenous ligands. Chemistry (2012) 0.86
Herbal-drug interaction induced rhabdomyolysis in a liposarcoma patient receiving trabectedin. BMC Complement Altern Med (2013) 0.86
Tumor microvasculature observed using different contrast agents: a comparison between Gd-DTPA-Albumin and B-22956/1 in an experimental model of mammary carcinoma. MAGMA (2008) 0.85
Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients. Cancer Chemother Pharmacol (2005) 0.85
Lapatinib/Paclitaxel polyelectrolyte nanocapsules for overcoming multidrug resistance in ovarian cancer. Nanomedicine (2011) 0.83
Clinical Evidence Supporting the Role of Lonidamine for the Treatment of BPH. Rev Urol (2005) 0.83
A new mutation of BRCA2 gene in an Italian healthy woman with familial breast cancer history. Fam Cancer (2011) 0.83
Medical treatment choices for patients affected by advanced NSCLC in routine clinical practice: results from the Italian observational "SUN" (Survey on the lUng cancer maNagement) study. Lung Cancer (2011) 0.82
Effect of tamoxifen in an experimental model of breast tumor studied by dynamic contrast-enhanced magnetic resonance imaging and different contrast agents. Invest Radiol (2005) 0.82
Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial. Oncologist (2006) 0.82
Equilibrium and kinetic properties of the lanthanoids(III) and various divalent metal complexes of the heptadentate ligand AAZTA. Chemistry (2009) 0.81
Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. Tumori (2012) 0.81
Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors. J Med Chem (2009) 0.81
Toxicological assessment of gadolinium release from contrast media. Exp Toxicol Pathol (2006) 0.81
Synthesis of Gd and (68)Ga complexes in conjugation with a conformationally optimized RGD sequence as potential MRI and PET tumor-imaging probes. ChemMedChem (2012) 0.81
In vivo tracking of murine adipose tissue-derived multipotent adult stem cells and ex vivo cross-validation. Int J Mol Imaging (2013) 0.81
Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study. J Cancer Res Clin Oncol (2014) 0.81
Time to first tumor progression as outcome predictor of a second trasuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancer. Breast J (2009) 0.80
BOLD fMRI integration into radiosurgery treatment planning of cerebral vascular malformations. Med Phys (2007) 0.80
New paramagnetic supramolecular adducts for MRI applications based on non-covalent interactions between Gd(III)-complexes and beta- or gamma-cyclodextrin units anchored to chitosan. J Inorg Biochem (2006) 0.80
Efficacy and safety of the combination of docetaxel (Taxotere) with targeted therapies in the treatment of solid malignancies. Curr Drug Targets (2009) 0.80
Preclinical profile and clinical potential of gadocoletic acid trisodium salt (B22956/1), a new intravascular contrast medium for MRI. Acad Radiol (2002) 0.80
Magnetic resonance contrast agents: from the bench to the patient. Curr Pharm Des (2005) 0.80
Pharmacokinetics and safety of gadobenate dimeglumine (multihance) in subjects with impaired liver function. Invest Radiol (2002) 0.79
Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemotherapy (HEC). Support Care Cancer (2015) 0.79
Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group. Cancer Chemother Pharmacol (2009) 0.78
Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancer. Breast Cancer Res Treat (2004) 0.78
3T MRI evaluation of the accuracy of atlas-based subthalamic nucleus identification. Med Phys (2008) 0.78
First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale. Lung Cancer (2009) 0.78
Damaging effects of gliadin on three-dimensional cell culture model. World J Gastroenterol (2005) 0.78
Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: are the two options alike? Med Oncol (2013) 0.78
MicroRNA expression in BRAF-mutated and wild-type metastatic melanoma and its correlation with response duration to BRAF inhibitors. Expert Opin Ther Targets (2015) 0.78
Pharmacokinetic and metabolism determinants of fluoropyrimidines and oxaliplatin activity in treatment of colorectal patients. Curr Drug Metab (2011) 0.77
An enzymatic approach to bifunctional chelating agents. Org Biomol Chem (2014) 0.77
Pharmacogenomics of cetuximab in metastatic colorectal carcinoma. Pharmacogenomics (2014) 0.77
Atlas-based identification of targets for functional radiosurgery. Med Phys (2006) 0.77
Attitude of Italian medical oncologists toward palliative care for patients with advanced cancer: results of the SIO project. Support Care Cancer (2010) 0.77
Novel plant-derived target drugs: a step forward from licorice? Expert Opin Ther Targets (2013) 0.77
How should we prescribe lapatinib to our patients: once daily or twice daily, and at what dose? J Clin Oncol (2008) 0.77
Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA). Lung Cancer (2010) 0.77
Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study. Tumori (2015) 0.77
Gadocoletic acid trisodium salt (b22956/1): a new blood pool magnetic resonance contrast agent with application in coronary angiography. Invest Radiol (2006) 0.77
X-ray fluorescence elemental mapping and microscopy to follow hepatic disposition of a Gd-based magnetic resonance imaging contrast agent. Clin Exp Pharmacol Physiol (2011) 0.77
Epirubicin and gemcitabine as first-line treatment in malignant pleural mesothelioma. Tumori (2005) 0.77
Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trial. J Transl Med (2003) 0.77
The one-step synthesis and surface functionalization of dumbbell-like gold-iron oxide nanoparticles: a chitosan-based nanotheranostic system. Chem Commun (Camb) (2015) 0.77
Margins of safety of intravascular contrast media: body weight, surface area or toxicokinetic approach? Arh Hig Rada Toksikol (2005) 0.77
Insight into the molecular properties of Chitlac, a chitosan derivative for tissue engineering. J Phys Chem B (2013) 0.76
Current status and future potential role of exemestane in the treatment of early and advanced breast cancer (Review). Int J Oncol (2002) 0.76
Multicenter phase II trial of first-line docetaxel/gemcitabine in advanced breast cancer pretreated with adjuvant anthracyclines. Anticancer Res (2009) 0.76
A tailored regimen including capecitabine and oxaliplatin for treating elderly patients with metastatic colorectal carcinoma Southern Italy Cooperative Oncology Group trial 0108. Crit Rev Oncol Hematol (2005) 0.76
Potent trophic activity of spermidine supramolecular complexes in in vitro models. World J Biol Chem (2013) 0.76
Hereditary ovarian cancers: from BRCA mutations to clinical management. A modern appraisal. Cancer Metastasis Rev (2010) 0.76
[Therapeutic decisions and treatment with sorafenib in hepatocellular carcinoma: final analysis of GIDEON study in Italy]. Recenti Prog Med (2015) 0.76
Second-line erlotinib for non-small-cell lung cancer. Lancet Oncol (2012) 0.75
Just say cancer. J Clin Oncol (2008) 0.75
Partial response of liver metastases treated with abiraterone in castration-resistant prostate cancer: A case report. Oncol Lett (2013) 0.75
Ovarian cancer biomarkers: a focus on genomic and proteomic findings. Curr Genomics (2007) 0.75
Synthesis of functionalised HP-DO3A chelating agents for conjugation to biomolecules. Org Biomol Chem (2009) 0.75
Communication near the end of life. Tumori (2008) 0.75
Effect of iomeprol on rat hippocampal slice synaptic transmission: comparison with other X-ray contrast agents. Invest Radiol (2002) 0.75
Biweekly combination of trastuzumab, docetaxel and gemcitabine for HER2-positive metastatic breast cancer: results of a Phase II GOIM study. Future Oncol (2014) 0.75